Insomnia drug from Merck raises FDA safety concerns
May 21, 2013 ( WASHINGTON) -- Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.
The Food and Drug Administration released its review of the company's sleep aid, suvorexant, ahead of a public meeting on Wednesday. The pill works by temporarily blocking chemical messengers that keep people awake.
The FDA said company trials show suvorexant was better than placebo at helping people fall asleep and stay asleep. Regulators said Monday the drug's effectiveness was consistent across several doses tested by Merck & Co.
But patients taking the highest dose of the drug showed an eight-fold increase in daytime drowsiness, which could interfere with driving the next morning. Suvorexant was also associated with increased risk of suicidal thinking.
- 2 shot, alleged hostage freed in Arlington Heights 8 min ago
- Brutal cold grips continues; more snow coming
- Mother charged in death of 7-month-old baby
- ABC7 Weather Forecast
- Man charged after boy allegedly brings gun to Elgin school
- Gun violence victims remembered at Roseland vigil
- Block 37 developers indicted on federal fraud charges
- Mariano's holds job fairs this week in city, suburbs
- Our Lady of Guadalupe celebration wraps up in Des Plaines
- Feds crack down on unsafe buses
- No retrial for alleged CPD torture victim Wrice
- Rally held to support CTA program that helps ex-convicts
- Mom charged after YouTube postings of alphabet lesson
- abcnews: More Teens Sought in Mansion Party